Compare Stocks: TCRX, CTOR, TELO, and ACRV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.85 +8.8%	$1.88	$1.27 ▼ $3.56	$79.28M	1.92	259,535 shs	477,361 shs
CTOR Citius Oncology	$1.14 +11.8%	$0.75	$0.49 ▼ $2.25	$106M	3.52	68,708 shs	336,868 shs
TCRX TScan Therapeutics	$0.31 -6.5%	$0.68	$0.29 ▼ $2.57	$21.14M	1.07	1.16 million shs	1.14 million shs
TELO Telomir Pharmaceuticals	$1.23 +9.8%	$1.15	$0.89 ▼ $2.09	$84.59M	-0.25	50,786 shs	480,410 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+8.82%	-7.50%	-22.59%	+17.83%	+18.59%
CTOR Citius Oncology	+11.76%	+24.25%	+51.50%	+70.23%	-35.96%
TCRX TScan Therapeutics	-6.48%	-2.65%	-58.41%	-66.10%	-80.51%
TELO Telomir Pharmaceuticals	+9.82%	+5.13%	+5.13%	-13.38%	-7.52%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.85 +8.8%	$1.88	$1.27 ▼ $3.56	$79.28M	1.92	259,535 shs	477,361 shs
CTOR Citius Oncology	$1.14 +11.8%	$0.75	$0.49 ▼ $2.25	$106M	3.52	68,708 shs	336,868 shs
TCRX TScan Therapeutics	$0.31 -6.5%	$0.68	$0.29 ▼ $2.57	$21.14M	1.07	1.16 million shs	1.14 million shs
TELO Telomir Pharmaceuticals	$1.23 +9.8%	$1.15	$0.89 ▼ $2.09	$84.59M	-0.25	50,786 shs	480,410 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	+8.82%	-7.50%	-22.59%	+17.83%	+18.59%
CTOR Citius Oncology	+11.76%	+24.25%	+51.50%	+70.23%	-35.96%
TCRX TScan Therapeutics	-6.48%	-2.65%	-58.41%	-66.10%	-80.51%
TELO Telomir Pharmaceuticals	+9.82%	+5.13%	+5.13%	-13.38%	-7.52%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	629.73% Upside
CTOR Citius Oncology	2.33	Hold	$6.00	426.32% Upside
TCRX TScan Therapeutics	2.13	Hold	$2.67	754.97% Upside
TELO Telomir Pharmaceuticals	2.50	Moderate Buy	$4.00	225.20% Upside

Current Analyst Ratings Breakdown

Latest TCRX, CTOR, TELO, and ACRV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/16/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/31/2026	CTOR Citius Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	TCRX TScan Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/12/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$3.57 per share	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	$0.54 per share	N/A
TCRX TScan Therapeutics	$10.32M	2.05	N/A	N/A	$2.16 per share	0.14
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	11/12/2026 (Estimated)
CTOR Citius Oncology	-$24.76M	-$0.47	N/A	N/A	N/A	N/A	-102.98%	-43.49%	N/A
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	12/2/2026 (Estimated)

Latest TCRX, CTOR, TELO, and ACRV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	CTOR Citius Oncology	-$0.07	-$0.08	-$0.01	-$0.08	$2.50 million	$1.49 million
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
CTOR Citius Oncology	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	7.99
CTOR Citius Oncology	0.25	0.73	0.34
TCRX TScan Therapeutics	0.31	3.37	3.37
TELO Telomir Pharmaceuticals	N/A	16.16	16.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
CTOR Citius Oncology	70.52%
TCRX TScan Therapeutics	82.83%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
CTOR Citius Oncology	9.82%
TCRX TScan Therapeutics	6.25%
TELO Telomir Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	76	42.85 million	38.35 million	Not Optionable
CTOR Citius Oncology	N/A	92.98 million	83.85 million	N/A
TCRX TScan Therapeutics	142	67.78 million	63.54 million	Not Optionable
TELO Telomir Pharmaceuticals	5	68.78 million	57.52 million	N/A

TCRX, CTOR, TELO, and ACRV Headlines

Recent News About These Companies

Maxim Initiates Telomir Pharmaceuticals at Buy With $4 Price Target

September 18 at 9:28 AM | marketscreener.comM

Telomir Publishes Data Validating Telomir-Zn For AMD Alongside Cancer Indications; Stock Up

September 17 at 6:34 PM | rttnews.com

Telomir-Zn Preclinical Data Highlight Retinal Regeneration Potential

September 17 at 9:11 AM | tipranks.com

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

September 17 at 8:30 AM | globenewswire.com

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 3.4% - Time to Sell?

September 17 at 1:41 AM | americanbankingnews.com

Telomir unveils new preclinical data for Telomir-Zn

September 14, 2026 | tipranks.com

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

September 14, 2026 | globenewswire.com

Telomir Pharmaceuticals (TELO) to Post Quarterly Earnings on Wednesday

August 26, 2026 | marketbeat.com

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

August 12, 2026 | defenseworld.netD

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

August 10, 2026 | markets.businessinsider.com

Telomir-Zn Preclinical Data Support Advancement in TNBC

August 10, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models

August 10, 2026 | quiverquant.comQ

TELO Telomir Pharmaceuticals, Inc.

July 8, 2026 | seekingalpha.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15, 2026 | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model

June 15, 2026 | accessnewswire.comA

Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change

June 8, 2026 | tipranks.com $https://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral$

Telomir Pharmaceuticals Inc TELO

May 26, 2026 | morningstar.comM

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease

May 20, 2026 | usatoday.com

Telomir-Zn Preclinical Data Published in Wilson’s Disease

May 20, 2026 | tipranks.com

Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease

May 20, 2026 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TCRX, CTOR, TELO, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.85 +0.15 (+8.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.92 +0.07 (+4.00%)

As of 09/18/2026 07:50 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Citius Oncology NASDAQ:CTOR

$1.14 +0.12 (+11.76%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.12 -0.02 (-1.40%)

As of 09/18/2026 07:58 PM Eastern

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

TScan Therapeutics NASDAQ:TCRX

$0.31 -0.02 (-6.48%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.32 +0.01 (+3.24%)

As of 09/18/2026 07:22 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Telomir Pharmaceuticals NASDAQ:TELO

$1.23 +0.11 (+9.82%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.21 -0.02 (-1.63%)

As of 09/18/2026 07:55 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRX, CTOR, TELO, and ACRV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRX, CTOR, TELO, and ACRV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRX, CTOR, TELO, and ACRV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TCRX, CTOR, TELO, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Citius Oncology NASDAQ:CTOR

TScan Therapeutics NASDAQ:TCRX

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TCRX, CTOR, TELO, and ACRV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TCRX, CTOR, TELO, and ACRV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TCRX, CTOR, TELO, and ACRV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TCRX, CTOR, TELO, and ACRV Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Citius Oncology NASDAQ:CTOR

TScan Therapeutics NASDAQ:TCRX

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools